Boehringer Ingelheim Exercised its Option to License Oxford Biomedica's Lentiviral Vector Technology to Commercialize BI 3720931 for CF
Shots:
- OXB to receive $4.83M as an option exercise fee & ~$37.96M in development- regulatory & sales milestones along with royalty on sales of a CF gene therapy product under an option & license agreement with Boehringer Ingelheim as reported in Aug’18
- Boehringer Ingelheim has also exercised its option to license IP from IP & UK Cystic Fibrosis Gene Therapy Consortium of lentiviral vector-based product for CF
- The collaboration focuses on the development of a lentiviral vector in an inhaled formulation to introduce a CFTR gene into the relevant target cell. OXB expects to produce large quantities of lentiviral vectors using a GMP-compliant manufacturing process in bioreactors
| Ref: Globe Newswire | Image: Franchise India
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com